

Sensorion to Present Three Posters on SENS-401 in Cisplatin Ototoxicity Models at the Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting

2/3/2022

- Sensorion will present three posters on SENS-401: Cisplatin-Induced Rat Ototoxicity Model; In Vitro and Ex Vivo Cisplatin Ototoxicity Models; SENS-401 Inner Ear Exposure
- ARO will be hosted virtually on February 5-9, 2022

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News:

Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce it will present three posters on SENS-401 in Cisplatin Ototoxicity models at the 2022 Association for Research in Otolaryngology (ARO) MidWinter Meeting. SENS-401 is Sensorion's oral small molecule lead asset, currently being investigated in sudden sensorineural hearing loss (SSNHL) and cisplatin-induced ototoxicity (CIO).

The three posters will be accessible under the following titles on the ARO MidWinter Meeting **website**:

- "Optimization of a Cisplatin-Induced Rat Ototoxicity Model: Comparison of Various Repeated Slow Intravenous Infusion Regimens Associated with Supplemental Rehydration Protocols for Optimized Long-Term Hearing Loss and Survival Rates"
- "In Vitro and Ex Vivo Cisplatin Ototoxicity Models to Identify New Drug Candidates to Restore Inner Ear Function"

- “SENS-401 Inner Ear Exposure is Not Altered by Severe Acoustic Trauma in a Rat Model of Sudden Sensorineural Hearing Loss (SSNHL)”

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept study of SENS-401 clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation.

Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has three gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, Usher Syndrome Type 1 related deafness and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

www.sensorion.com

About SENS-401

SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequela hearing impairment. A small molecule that can be taken orally or via an injection, SENS-401 has received Orphan Drug Designation in Europe for the treatment of sudden sensorineural hearing loss, and Orphan Drug Designation from the US FDA for the prevention of platinum-induced ototoxicity in pediatric population. It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA).

About ARO

The Association for Research in Otolaryngology (ARO) is the world's largest organization of hearing and balance researchers both fundamental and clinical. The ARO Midwinter meeting is held each year and is the primary meeting of the association.

Label: **SENSORION**

ISIN: **FR0012596468**

Mnemonic: **ALSEN**

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2020 annual financial report published on April 9, 2021 and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

Investor Relations

Catherine Leveau

Head of Investor Relations & Communication

ir.contact@sensorion-pharma.com

+ 33 6 72 18 00 22

International Media Relations

ConsiliumStrategic Communications

Mary-Jane Elliott/Jessica Hodgson

+ 44 7739 788014 +44 7561 424788

Sensorion@consilium-comms.com

Source: Sensorion